Tumor Rupture During Robotic Partial Nephrectomy

Launched by AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA · Jul 11, 2025

Keywords

ClinConnect Summary

This study, called the RUPTURE Project, is looking at a specific complication that can happen during a type of kidney surgery called robotic partial nephrectomy, which is used to remove kidney tumors. Sometimes, the tumor’s outer layer accidentally breaks open during the surgery—a situation known as tumor rupture. This happens in about 10-15% of cases, but doctors don’t yet fully understand how this might affect the patient’s chances of the cancer coming back or spreading. The study aims to gather information from at least 100 patients who have experienced this rupture to learn more about what causes it, how it is managed during surgery, and what the long-term outcomes are.

Adults between 18 and 80 years old who have had this type of surgery and experienced tumor rupture may be eligible to take part, as long as they agree to join the study. Participants will receive the usual care for their condition, and the study will simply collect information about their health, the surgery, and follow-up visits over five years to track cancer recurrence or spread. There are no extra tests or treatments involved. This research hopes to help doctors improve surgical techniques and patient safety in the future. Participation is voluntary, and all personal information is kept confidential.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who experienced tumor rupture during RAPN (referred to an unintended breach of the tumor capsule with or without spillage of malignant tissue during tumor resection)
• • Patients who provide informed consent to participate
• • Patients from 18 to 80 years of age.
• Exclusion Criteria:
• • Patients undergoing radical nephrectomy or other nephron-sparing procedures.
• • Patients undergoing partial nephrectomy with other approaches (open, pure laparoscopic)
• • Patients with multiple ipsilateral tumors
• • Patients diagnosed with genetic abnormalities that increase the likelihood of developing renal cell carcinoma.
• • Patients who deny consent.